Loading patent…
AssigneeAlbany Medical College
InventorsEdmund J. Gosselin, Sudeep Kumar, David Nalin
Estimating the term…
Peripheral blood mononuclear cells (PBMCs) can be used in place of DCs when pulsing with antigens, or antigen and adjuvant combination, and then administered to a subject as a vaccine to induce a protective immune response. The PBMC-based vaccine strategy provides a more marked and enduring protective immune response and is also capable of serving as a multi-organism prophylactic vaccine platform. The vaccine platform may be used to screen vaccine and adjuvant combinations and may also be used to allow for adjuvants that are otherwise unsafe for use in humans as the adjuvant may be removed prior to prophylactic administration of the pulsed PBMCs.
A system for providing a protective immune response in a subject, comprising a therapeutic amount of peripheral blood mononuclear cells that have been pulsed ex vivo with at least one antigen and an adjuvant, wherein the therapeutic amount of peripheral blood mononuclear cells does not include the vaccine and the adjuvant.
A method of screening a vaccine and adjuvant combination, comprising the steps of:
A method of immunizing a subject, comprising the steps of:
Dependencies are inferred from the claim text.